On June 2, 2026, Suzhou XueJi Biotechnology Co., Ltd. made a significant announcement: it had successfully concluded the second closing of its Series B financing round. This latest phase of funding saw the company attract over RMB 100 million in new investments, elevating the total Series B funding to a substantial sum of nearly RMB 300 million. Prior to this, the company had already officially declared the completion of the first closing of its Series B1 round, which also garnered over RMB 100 million. Remarkably, it managed to achieve the second closing within approximately four months, adhering to its planned timeline.

This round of financing was spearheaded by prominent new investors, including Shenzhen Capital Group and Hebei Industrial Investment. Among the existing investors, CDH Investments and Weidu Capital continued their support by participating as follow-on investors. It is worth mentioning that Weidu Capital has been a steadfast lead investor since the company's seed round and has actively participated in multiple funding rounds.

The proceeds from this financing will be strategically allocated to advance clinical trials for multiple indications of the world's pioneering megakaryocyte injection. Additionally, the funds will fuel the development of pipeline products such as platelet injections, with the overarching goal of addressing blood supply shortages and blood-borne diseases, while simultaneously minimizing adverse transfusion outcomes. Moreover, the investment will support the exploration and development of innovative platelet-derived drugs aimed at tackling aging-related medical conditions.

Following this successful financing round, XueJi Biotechnology has outlined its plans to initiate a Pre-IPO funding round within the year. This strategic move is intended to bolster the establishment of its production base and expand its manufacturing capabilities, thereby laying a solid foundation for the company's future growth and market presence.